Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use by Gladstone, Beryl Primrose et al.
RESEARCH ARTICLE
Antimicrobial resistance rates in gram-
positive bacteria do not drive glycopeptides
use
Beryl Primrose Gladstone1, Andrea Cona1,2, Parichehr Shamsrizi1, Tuba Vilken1, Winfred
V. Kern3, Nisar Malek1, Evelina Tacconelli1*
1 Infectious Diseases, Department of Internal Medicine I, DZIF Partner, Tu¨bingen University Hospital,
Tu¨bingen, Germany, 2 Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan,
Milan, Italy, 3 Infectious Diseases, Department of Medicine, University Hospital and Medical Center and
Albert-Ludwigs-University Faculty of Medicine, Freiburg, Germany
* Evelina.Tacconelli@med.uni-tuebingen.de
Abstract
Surveillance data are considered essential to appropriate empiric antibiotic therapy and
stewardship. The objective of this study was to determine if a change in the rates of antibiotic
resistance impacts antibiotic use in European hospitals. Glycopeptides use was selected to
study the correlation between resistance rates and antibiotic use because of the restricted
spectrum against resistant gram positive bacteria. PubMed, ECDC databases and national/
regional surveillance systems were searched to identify glycopeptides´ consumption in
defined daily dose per 1000 inhabitant-days (DID) and rate of methicillin-resistant Staphylo-
coccus aureus (MRSA), methicillin-resistant coagulase negative staphylococci (MRCoNS),
and vancomycin-resistant enterococci (VRE) in bloodstream infections (BSIs) in European
countries between 1997 and 2015. Time trends were studied and associations between DID
and BSI resistance rates were tested using multi-level mixed effect models. To account for
the gap in the publication and dissemination of the yearly resistance data, a 2-year lag in the
resistance rates was applied. Data on glycopeptides´ DID and resistance rates of target
microorganisms in blood cultures were identified among 31 countries over a 19-year period.
Glycopeptides use significantly increased (p<00001) while rates of MRSA BSIs decreased
in majority of the countries (p<00001) and MRCoNS and VRE BSIs remained stable. Varia-
tion in glycopeptides’ DID was not associated with variation in BSIs due to MRSA (p =
0136) and VRE (p = 0613). After adjusting for MRCoNS and VRE resistance rates, among
21 countries, 11 (52%) had a concordant and 10 (48%) a discordant trend in yearly glyco-
peptides´ DID and MRSA BSI rates. No correlation was found between resistance rates and
DID data even among 8 countries with more than 5% decrease in MRSA rates over time.
(RC -0009, p = 0059). Resistance rate of MRSA, MRCoNS, and VRE BSIs does not impact
DID of glycopeptides in European hospitals. This finding is key to redefining the role and
structure of antimicrobial surveillance and stewardship programmes.
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Introduction
Rising global resistance rates and emergence of new resistance mechanisms, along with an
almost empty antibiotic drug discovery pipeline, are creating a dramatic scenario in hospitals
worldwide.[1, 2] In Europe, bloodstream infections (BSIs) due to antibiotic-resistant organ-
isms have been estimated to kill about 25,000 people and to add about 15 billion euros of
additional healthcare costs and productivity losses every year.[3] To address this problem,
multifaceted approaches, such as antimicrobial stewardship programme and antimicrobial
resistance (AMR) surveillance, have been implemented in many hospitals with variable results
for efficacy and costs.[2, 4–6] Essential components of these programmes are active monitor-
ing of resistance and fostering of appropriate antimicrobial use that optimises patients´ clinical
outcomes while minimising unintended consequences of antimicrobial use, including toxicity
and the emergence of resistance.[7, 8]
Updated information from AMR surveillance systems plays a pivotal role in this approach.
Knowledge of surveillance data should improve public health at different levels, from the local
(patients’ clinical outcomes) to the more global (hospital and community AMR rates) perspec-
tive. Indeed, data from global surveillance systems should provide information on new worri-
some AMR trends and allow policymakers at national and international level to design new
strategies to face the threat.[9] Yearly European surveillance data are publicly available from
the European Centre for Disease Prevention and Control (ECDC)[10] as well as from many
national cohorts.[11–13] However, data linking the antibiotic use and availability of surveil-
lance data of target microorganisms are not available.
We did an observational ecological study to ascertain the association between trends in
antibiotic use and AMR surveillance data in hospitalised patients in European countries.
Materials and methods
Outcomes
Glycopeptides use was selected to study the correlation between resistance rates and antibiotic
use because the restricted spectrum of these intravenous drugs covers mainly severe infections
due to methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-
negative staphylococci (MRCoNS) and vancomycin-susceptible enterococci (VSE). Selection
of other antimicrobial classes would have involved a wider bacterial spectrum and introduced
confounding in the correlation analysis.
The primary outcomes of this study were the yearly resistance rates of MRSA, MRCoNS,
and VRE in BSI expressed as percentages and glycopeptides use expressed as defined daily
dose (DDD) per 1000 inhabitant–days (DID). Rate of MRSA is defined as the proportion of
methicillin resistance among S. aureus isolates while rate of VRE as the proportion of vanco-
mycin resistance among enterococci isolates. When available, antibiotic use data were also
collected as other measures such as recommended daily dose per 100 patient-days or DDD
per 100 occupied bed-days. Measures other than DID were used only for within-country com-
parisons over time and not for inter-country analyses. When glycopeptides use data were not
available, vancomycin data were used instead. VRE rates were used to represent VSE for con-
sistency within the paper with MRSA and MRCoNS data.
Study design
We performed an ecological observational study and searched yearly national surveillance
data for glycopeptides´ DID and rates of BSIs due to MRSA, MRCoNS and VRE. The target
population was hospitalised patients in 31 European countries over a 19 year-period (1997–
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2015). Data were first extracted from the European Antimicrobial Resistance Surveillance Net-
work (EARS-Net)[14] database and the European Surveillance of Antimicrobial Consumption
(ESAC). [15] To reduce potential errors in measurement we contacted experts from the Euro-
pean Society of Infectious Disease and Clinical Microbiology (ESCMID); we developed a stan-
dardized protocol to search online information on surveillance systems and to address experts;
and interviewers (BPG and TV) were trained to ask relevant questions. For the European
countries for which EARS-Net or ESAC data were not available or incomplete for the study
period, a literature search using Pubmed was conducted to identify national / regional surveil-
lance systems or cohort studies focused on BSIs surveillance and/or antibiotics use in hospital-
ised patients. Reports of ECDC point-prevalence surveys [10] were also searched.
Statistical analysis
We included only countries with more than four data points of yearly rates of target microor-
ganisms in blood cultures and glycopeptides´ DID during the study period in the analysis. The
longitudinal data on resistance rates and glycopeptides usage expressed as log-transformed
DID consumption were tested for time trends using linear trend analysis and we report the
yearly change (YC) of resistance rates as well as the rate of yearly change (RYC) of glycopep-
tides´ DID assuming linearity. The overall time trend as well as inter-correlation of resistance
rates and glycopeptides usage were studied using multilevel mixed-effect linear models allow-
ing for a random variance at the yearwise and countrywise estimates to account for interde-
pendence of data. To account for the gap in the publication and dissemination of the yearly
resistance data to the medical community, a 2-year lag in the rates was applied. The regression
coefficients (RC) refer to the change in log transformed glycopeptide consumption with a unit
change in the rate of a specific resistant strain. Thus confounding effects of rates of other resis-
tant strains and delay in publication were adjusted for in the analyses. Final analysis was
restricted to the period from 2005 until 2015 since the downward trend of the MRSA preva-
lence per 1000 patient days in Europe was reported for the first time in 2005[16].
Additionally, correlation between glycopeptides‘DID and resistance rates of BSIs due to
MRSA, MRCoNS, and VRE were classified as discordant or concordant trends on the basis of
the direction of the relative change in glycopeptides‘DID and in the BSI resistance rates for
each European country. Pairwise deletion of missing data was performed. The statistical analy-
ses were conducted using STATA version 14.0.[17]
Results and discussion
Overall, we mapped 13 surveillance systems addressing resistance among targeted bacteria and
antibiotic consumption (S1 Table). Relevant data (S1 File) were extracted for 31 countries
from 6 surveillance systems. Incomplete or partial data from the EARS and ESAC databases
were integrated with 4 national or regional surveillance systems. Table 1 illustrates the main
characteristics of the surveillance systems.
MRSA-BSI
Data on MRSA rate could be retrieved from the EARS-Net for 28 countries while incomplete
data were retrieved for Croatia (data available only from 2010 onwards) and Slovakia (missing
data from 2006 to 2010). Data were not available for one country (Liechtenstein).
Over the study period, MRSA rate significantly decreased (YC: -0510; p<00001) ranging
from 0% to 65% of S. aureus BSI. Iceland, Norway, Sweden, Netherlands, Denmark, and
Finland had resistance rate of<2% while Slovakia, Cyprus, Italy, Greece, Portugal, Malta,
and Romania had resistance rates of>25%. Correlation coefficients showed a significant
Antimicrobial resistance rates and usage
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decreasing trend in MRSA rates in Austria (p = 0.045), Belgium (p<00001), France (p<
00001), Germany (p = 00006), Greece (p = 0.029), Ireland (p<00001), Latvia (p = 00047),
Malta (p = 00092), Spain (p = 0024), and the UK (p<00001). Except for increasing trend in
Slovakia and a subtle increase in Norway, MRSA rates either decreased (although not signifi-
cantly) or remained stable in the other countries. Table 2 displays trends per analysed country.
MRCoNS BSI
The EARS-Net database does not report data on the rate of BSI due to CoNS. Literature search
identified one national surveillance system from France (ONERBA; Observatoire National de
l’E´pide´miologie de la Re´sistance Bacte´rienne aux Antibiotiques) reporting yearly prevalence
data from 1996 to 2011. Analysis of these data showed a stable trend of BSI due to MR-CoNS.
In order to increase representativeness of data, we searched the ECDC point-prevalence
surveys that provided data on the resistance rate of CoNS-BSI in intensive care unit (ICU) for
15 countries at three time points: 2004–2005, 2007, and 2012. At least two time points were
available for ten countries (Austria, Belgium, France, Germany, Italy, Lithuania, Luxembourg,
Portugal, Slovakia, and Spain). Since ICU BSIs are a primary contributor to CoNS infections
and a high proportion of CoNS BSI (> 80%) are resistant to methicillin, these data were used
as surrogate data to represent the rate of MRCoNS BSIs in hospitalized patients.
The overall rate of CoNS among ICU BSIs in Europe remained stable being 294% in 2004–
2005, 285% in 2007, and 223% in 2012. Except for Lithuania and Austria, which had a non-
significant increase in this period, the data showed a non-significant decreasing trend from
2004 to 2012 in the other countries.
VRE BSI
VRE rate data could be retrieved from the EARS-Net for 28 countries while incomplete data
were retrieved for Croatia (data available only from 2010 onwards) and Slovakia (missing data
from 2006 to 2010). Data were not available for one country (Liechtenstein).
During the study period, the overall rate of VRE slightly increased (YC 0.2055, p = 0.046)
ranging from 05% to 43%. Ireland, the UK, Cyprus, Greece, and Portugal reported a resistance
rate of>15% and 15 countries had a resistance rate of< 5%. While France (p = 0018), Greece
(p = 0.002), and Portugal (p = 0001) showed a significant decreasing linear trend, Austria
(p = 0012), Bulgaria (p = 0016), Denmark (p = 0001), Hungary (p = 0003), Ireland (p =
00001), Latvia (p = 0034), Netherlands (p = 0020), Poland (p = 00007), Romania (p =
0004), and Slovakia (p = 0019) displayed a significant increasing trend between 2005 and
Table 1. National surveillance systems and European research projects reporting surveillance data on bloodstream infections (BSIs) due to meth-
icillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase negative staphylococci (MRCoNS), and vancomycin-resistant
enterococci (VRE) included in the study.
Surveillance system Acronym Country Coverage
European Antimicrobial Resistance Surveillance Network[14] EARS-Net Europe 30 European countries
European Surveillance of Antimicrobial Consumption[15] ESAC Europe 30 European countries
English surveillance programme for antimicrobial utilisation and resistance[12] ESPAUR England 160 national acute-care
hospitals
Observatoire National de l’E´ pide´miologie de la Re´sistance Bacte´rienne aux Antibiotiques[13] ONERBA France 15 microbiological
networks
Surveillance of Health Care Associated Infections in Catalonia[18] VINCat Catalona
(Spain)
54 hospitals
Surveillance Project for Antibiotic Use in German Acute Care Hospitals (Bunderverhand
Deutscher Krankenhaus Apotheker e.V) [19]
RKI-if-
ADKA
Germany 109 acute-care hospital
centres
https://doi.org/10.1371/journal.pone.0181358.t001
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2015. Croatia and Lithuania showed an increasing though not significant trend (p = 0159 and
p = 0109 respectively).
Glycopeptides´ DID
Glycopeptides use data expressed as DID could be retrieved from the ESAC database for 23
countries. Due to the lack of national available data, the following regional data were used: the
Table 2. Time trends of rates (%) of methicillin resistance among Staphylococcus aureus and vancomycin resistance among enterococci isolates
from bloodstream infection (BSI) and glycopeptides use expressed as Defined Daily Dose per 1000 inhabitant–days (DID) for European countries
during 11-year period (2005 to 2015).
MRSA VRE Glycopeptide consumption (GC)
(expressed in DID)*rates rates
(%) (%)
Country Yearly change P Yearly change P value Annual change in log GC Rate of yearlychange (RYC) P
Value Value
Austria -0.377 0.0445 -0.374 0.0108
Belgium -1.455 0.0001 0.646 0.0757 -0.025 0.975 0.0012
Bulgaria -0.885 0.0886 -1.147 0.0155 0.127 1.135 <0.0001
Croatia -0.700 0.2998 -3.163 0.1593 0.068 1.070 0.2074
Cyprus -1.015 0.1826 -0.077 0.9562
Czech Republic 0.047 0.5305 0.031 0.9221
Denmark 0.038 0.426 -0.387 0.0011 0.064 1.066 0.0009
Estonia -0.025 0.9216 0.086 0.2854 0.097 1.102 0.0001
Finland -0.067 0.2461 0.027 0.0629 0.008 1.008 0.3851
France -1.219 <0.0001 0.200 0.0178 -0.003 0.997 0.3312
Germany -0.913 0.0006 -0.276 0.4436 0.067 1.069 0.0074
Greece -0.555 0.0288 2.008 0.0016 -0.010 0.990 0.0632
Hungary 0.178 0.5467 -1.218 0.003 0.052 1.054 0.0077
Iceland -0.059 0.8027 -0.041 0.8946
Ireland -2.628 <0.0001 -1.413 0.0001 0.119 1.127 0.0017
Italy -0.209 0.2763 0.891 0.0912 0.140 1.150 0.0629
Latvia -1.075 0.0047 -1.385 0.0336 0.032 1.032 0.0424
Lithuania -0.429 0.1505 -0.995 0.1092 0.095 1.100 0.3302
Luxembourg -0.600 0.161 0.175 0.897 -0.013 0.987 0.2036
Malta -1.472 0.0092 0.027 0.1215 0.070 1.072 0.0017
Netherlands 0.015 0.6832 -0.067 0.0197 0.033 1.034 0.0001
Norway 0.098 0.0046 -0.079 0.2618 0.081 1.085 <0.0001
Poland -0.038 0.9367 -1.878 0.0007 -0.123 .
Portugal 0.006 0.9845 1.074 0.0013 0.010 1.010 0.2997
Romania 1.496 0.2319 -2.336 0.004
Slovakia 1.194 0.0099 -1.246 0.0187 0.146 1.157 <0.0001
Slovenia 0.221 0.2609 0.329 0.383 0.024 1.024 0.0014
Spain -0.341 0.0242 0.104 0.2855 0.063 1.065 0.1171
Sweden 0.008 0.6915 0.054 0.2762 0.039 1.040 0.0001
United Kingdom -3.634 <0.0001 0.862 0.2462 0.090 1.095 0.0011
* For Spain and Germany, glycopeptides consumption data presented as DDD per 100 occupied bed days and recommended daily dosage per 100 patient-
days respectively
https://doi.org/10.1371/journal.pone.0181358.t002
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English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2014
report for UK[12]; the Catalonia surveillance data for Spain [20] and the RKI-if-ADKA GER-
MAP (Antibiotic use and the spread of antibiotic resistance in human and veterinary medicine
in Germany) for Germany.[19] Data were not available for five countries (Austria, Cyprus,
Czech Republic, Iceland, and Liechtenstein). Overall, at least four time points were available
for 24 countries.
During the study period, glycopeptides´ DID significantly increased at a rate of 1.058
(p<00001) ranging from 0.975 in Belgium to 1.150 in Italy per year. Ireland, Greece, and Italy
had the highest use (> 0.05 DID) while Bulgaria, Estonia, and Norway had the lowest use
(< 0.015 DID). Table 2 displays trends per analysed country.
In Spain and Germany, glycopeptides use data were presented as DDD per 100 occupied
bed days and recommended daily dosage (RDD) per 100 patient days respectively. Measures
other than DID were used only for within-country comparisons over time and showed an
increasing trend for both countries.
Glycopeptides´ DID and BSI resistance rates
Since MRSA rates and glycopeptides data were available throughout the study period for the
majority of the European countries (21/31), these data were used for the modelling. Fig 1
shows the MRSA, VRE and glycopeptides’ DID trends. To account for the gap in the publica-
tion and dissemination of the yearly resistance data to the medical community, a 2-year lag in
the resistance rates was applied. Mixed-effect modelling did not show a relationship between
glycopeptides use and MRSA rates (RC -0005, p = 0136). Similarly, modelling of glycopep-
tides use and VRE rates did not show any association (RC 0003, p = 0613). To account for the
variation in resistance rates, European countries were stratified according to the entity of the
reduction / increase in the MRSA rates in the study period. In the 8 countries with more than
5% decrease of MRSA BSI, no positive correlation could be observed, rather a negative correla-
tion, with glycopeptides’ DID (RC -0009, p = 0059) reflecting the contrasting trend between
MRSA and glycopeptides. Fig 2 shows the concordance and discordance of MRSA and glyco-
peptides’ DID trends after adjusting for VRE and MRCoNS rates data. Strikingly contrasting
trends of MRSA rates and glycopeptides DID were observed in 8 European countries.
Discussion
Our study revealed that between 2005 and 2015, yearly glycopeptides use in European coun-
tries significantly increased irrespective of the decreased trend in rates of BSIs due to MRSA
and VSE and stable trend of those due to MRCoNS (most important targets for these antibiot-
ics) in the same countries.
The dramatic increase in antimicrobial resistance in gram negative bacteria recently urged
the medical community to promote the implementation of antimicrobial stewardship pro-
grammes in hospitalised and community patients and to ask for new antibacterial drugs, to
require enhanced infection control measures in high risk hospitalised patients[21]. Of great
concern is the increased mortality rate reported in patients with severe infections and inappro-
priate antibiotic therapy [22–24] that ranged from 11% to 72% of treated patients. A gold stan-
dard to increase rationale antibiotic usage and implement antimicrobial stewardship
programmes however does not exist. Different approaches have been suggested with heteroge-
neous results including dedicated hospital teams, continuous education, antibiotic formulary,
rapid diagnostic tests, decision support systems, and periodic audits[21]. Interestingly, in all
these approaches, availability of updated surveillance data are the “sine-qua-non” condition to
improve the coverage of the most likely infecting microorganism. For this reason in the last
Antimicrobial resistance rates and usage
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decades major stakeholders at national and international levels made an enormous effort to
increase national coverage and representatives of surveillance systems of healthcare associated
and antimicrobial resistant infections.
The recent NICE[25] and IDSA[8] guidelines for antibiotic stewardship programmes recom-
mend that knowledge of the local AMR rates be taken into consideration for the empiric therapy.
However, although the AMR rates in European countries are updated yearly and disseminated
widely by the ECDC and by national surveillance systems, our findings suggest an incorrect per-
ception of the rates by the physicians leading to overprescription. A number of potential expla-
nations exist. First, fear of the clinical consequences of antibiotic-resistant infections and a lack
of effective point-of-care diagnostics for BSIs may lead to an increase in prescription of wide-
spectrum antibiotics in empiric therapy. Lack of de-escalation protocols incorporating microbio-
logical results as soon as they are available may also add to the burden of inappropriate therapy.
It is also worthy to note that a high percentage of antibiotic use is in patients with no final micro-
biological diagnosis, therefore increasing the risk of inappropriate therapy.
The 2005 EARS-Net surveillance report[14] showed a decrease in MRSA BSIs in hospital-
ized patients for the first time. This change has been attributed partly to the success of infection
control programs, although, because of the high heterogeneity in infection control procedures
in European countries, major drivers of reduction were difficult to define.[16] The increase in
Fig 1. Trends of rates of methicillin resistance among Staphylococcus aureus isolates and rates of
vancomycin resistance among enterococci isolates from bloodstream infection (BSI) and
glycopeptides use expressed as Defined Daily Dose per 1000 inhabitant–days (DID) for European
countries during 19-year period (1997 to 2015).
https://doi.org/10.1371/journal.pone.0181358.g001
Antimicrobial resistance rates and usage
PLOS ONE | https://doi.org/10.1371/journal.pone.0181358 July 20, 2017 7 / 11
vancomycin use had already been observed in 1984–1996 data from US and European mar-
kets.[26] Increase in vancomycin use in countries with decreasing MRSA rate had been
observed in Japan[27], France[28], and Hong Kong.[29] Recently, Grau et al[20] analyzed the
association between the consumption of anti-MRSA antibiotics and incidence of MRSA in 54
acute care hospitals in Catalonia from 2007 to 2012 and reported a steady increase in the van-
comycin use despite a stable MRSA burden. Data from German ICUs over a period of nine
years (2001 to 2009)[30] showed an overall increase in the use of antibiotics effective against
MRSA although the incidence rate and the proportion of MRSA did not change significantly
over time. Conversely, a US study[31] of treatment of MRSA wound infections showed that
the proportion of the variation of antimicrobial (linezolid, clindamycin, trimethoprim-sulfa-
methoxazole, and cephalexin) use was explained by the national and local MRSA burden.
Major limitations of the studies rely on the lack of accounting for confounders (e.g., VSE inci-
dence and regional or country data). To reduce these limitations and improve evidence on sur-
veillance impact on prescribing, we designed a study that analyses 31 European countries over
a 16-year period and include multiple microrogansims’ resistance data to cover all antibiotic
(in our case glycopeptides) therapeutic targets.
The study has limitations. First, the ecological design and the heterogeneity of sources
increase the risk of information biases, internal validity, and confounding (i.e. case mix of
Fig 2. Concordant (green countries) and discordant (red countries) trends in MRSA BSI rates and
glycopeptides use adjusted for trend in CoNS and VRE BSI rates in Europe in the study period. The
colours represent the European countries with Red: discordant trend between glycopeptide consumption and
prevalence rate of BSI due to MRSA, VSE and CONS / a concordant trend with a difference of more than
100% between the relative increase in glycopeptide consumption and relative increase in prevalence rates;
Discordant trend defined as opposing trends between between glycopeptide consumption and prevalence
rate of BSI due to MRSA, VSE and CONS with a difference of more than 50% in relative increase / relative
decrease; Green: concordant trend between the glycopeptide consumption and prevalence rates of BSI;
Yellow: No information available.
https://doi.org/10.1371/journal.pone.0181358.g002
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patients or usage of glycopeptides for the treatment of severe infections due to other drug-
resistant Gram-positives not included in our epidemiological analysis). Regarding the infor-
mation bias, ESAC network uses sources based on national sales and reimbursement data,
including information from national drug registries. Although 70% of the hospital data sources
in 2012 used standardised operative procedures to homogenize and validate case ascertain-
ment and definitions, sampling and laboratory procedures, an over- or under-estimation of
resistance rates is still possible. ECDC reports a high coverage of the total hospitalised popula-
tion based on their data sources.[32] Note of worthy, although the study was limited to BSI,
there is no data showing an increase of MRSA pneumonia or skin infections in Europe in
the last years. Second, there are no surveillance data on sepsis syndromes with no identified
micro-organism or for cases where no blood cultures were taken before starting empiric ther-
apy with glycopeptides. Third, antimicrobial consumption data were not adjusted for age and
weight. The national/regional data were extracted from retrospective and cohort studies and
therefore were potentially subject to inaccuracy and confounding. Fourth, the use of DDD
could be associated to intrinsic bias [33], although in this study this measure was used only for
trend comparison and not as an outcome measure. It is also important to note that we were
limited by the unavailability of MRSA incidence. However, recent data clearly showed a signif-
icant downward trend from 2005 onwards [16].
Future research should investigate the behavioural determinants connected with the incom-
plete usage of the surveillance data when prescribing empiric therapy in hospitalised patients
and explore cost-effectiveness of new surveillance tools including automated and semi-auto-
mated surveillance, inclusion of patient-level data, creation of network of networks (to assure
tracing of resistance spreading), and creation of sentinel-laboratories that in real time could
provide alert for new resistance pattern.
Conclusions
With ongoing intensive efforts to reduce and control the use of antimicrobials in Europe to
reduce AMR rates, our finding of increasing trends in glycopeptides use despite decreases in e
rates of BSIs due to MRSA, MRCoNS, and VSE are worrisome and seems to suggest a partial
consideration of the epidemiological data on resistance when prescribing glycopeptides in hos-
pitalised patients. The results of our study could play a significant role in the discussion of
components of antimicrobial stewardship programmes. The increasing local vancomycin use
should be therefore carefully evaluated in planning and implementing antimicrobial steward-
ship programmes. Prospective study addressing confounding factors and clinical patients data
need to be planned in order to understand. Reasons for these trends need to be explored and
corrective actions necessary for change to be taken. In our opinion a global effort, including
major international and national stakeholders, is required to improve understanding of and
access to surveillance data by doctors in clinical daily life.
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